BEDFORD, Mass. (May 4, 2009) – Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the quarter ended March 28, 2009.
Highlights of the quarter include:
Revenues of $402.0 million.
> Second quarter 2009 net loss was $2.3 billion or $8.97 per diluted share, calculated in accordance with U.S. generally accepted accounting principles (GAAP). This net loss was the result of $2.34 billion of charges relating to the write-down of certain of the Company’s goodwill and intangible assets.
> Second quarter 2009 non-GAAP adjusted net income was $74.1 million or $0.29 per diluted share, and adjusted EBITDA (non-GAAP adjusted earnings before interest, taxes, depreciation and amortization) was $144.9 million. A reconciliation of GAAP to non-GAAP results is included as an attachment to this press release.
> Term loan to fund the Third Wave Technologies acquisition reduced from an initial balance of $540 million at July 24, 2008 to $377 million as of March 28, 2009 and further reduced to $330 million as of today.
> Approval of the Company’s premarket approval (PMA) applications for both the Cervista HPV HR (high risk) and Cervista HPV 16/18 tests by the U.S. Food and Drug Administration (FDA).
